ReHealth’s development programs in Gastroenterology are focused on advancing new treatments in constipation and diabetic gastroparesis. Key programs include low-dose and colonic release formulations for Linzess and relamorelin, a novel treatment for Diabetic Gastroparesis, a debilitating condition that has not had a new therapeutic option in more than 30 years.

In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray) as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.